![iTeos Therapeutics Inc](/common/images/company/N_ITOS.png)
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.205 | 1.25766871166 | 16.3 | 17.71 | 15.56 | 293227 | 16.75555216 | CS |
4 | 1.655 | 11.1447811448 | 14.85 | 17.71 | 13.06 | 363313 | 15.33509631 | CS |
12 | 5.675 | 52.4007386888 | 10.83 | 18.75 | 10.6039 | 469482 | 16.08094976 | CS |
26 | 5.845 | 54.8311444653 | 10.66 | 18.75 | 9.7 | 362576 | 14.09431991 | CS |
52 | 1.925 | 13.2030178326 | 14.58 | 18.75 | 8.2 | 400640 | 12.45800518 | CS |
156 | -8.615 | -34.2953821656 | 25.12 | 52.43 | 8.2 | 360718 | 20.65610582 | CS |
260 | -3.195 | -16.2182741117 | 19.7 | 52.43 | 8.2 | 340143 | 22.11601357 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.